Site Map
Pages
News
About
- Celgene History
- Compliance
Bolder Science
Celgene Corporate Responsibility
- CDP (Carbon Disclosure Project) Reports
- Patients First
- Patient Safety, Support & Advocacy
- Patient Safety
- 2019 Innovation Impact Award
- Celgene Cooperation With European Patient Organizations
- EFPIA Spend Transparency Disclosure
- Advocacy Partnerships
- Patient Safety, Support & Advocacy
- Pre-Approval Access
- Global Health
- Patient Support
- Business with Integrity
- Funding
- Corporate Responsibility Reports
Community Guidelines
Contact Us
Diseases
- Acute Myeloid Leukemia
- Beta Thalassemia
- Indolent NHL
- Multiple Myeloma
- Beh?et’s Disease
- Multiple Sclerosis
- Myelofibrosis
- Myelodysplastic Syndromes
- Pancreatic Cancer
- Psoriasis and Psoriatic Arthritis
Global Office Locations
Home Page
Investors
Medical Professionals
Newsroom
Patients
Patients’ Partners at SABCS 2019
Patients’ Partners Event at ASH 2019
Privacy Policy
Research & Development
- Pipeline
- Medical Innovation
- Research & Development Centers
- Clinical Trials
- Celgene Global Drug Safety and Risk Management
- Celgene Medical Affairs
- Registry Studies
Thanks for Verifying
Therapies
October 30, 2019
Light The Night: How To Organize 1 Million People to Fight Blood Cancer
October 18, 2019
Understanding the Complexities of a Myelofibrosis Diagnosis
October 18, 2019
Get To Know JAK2 and Its Role in Myelofibrosis
October 18, 2019
Care Partners Offer Critical Insights into Cognitive Symptoms of Multiple Sclerosis
September 4, 2019
Blood Cancer Awareness Month: Fulfilling a Long-term Goal
July 12, 2019
Giving People with Disabilities a Much-Needed Accessibility Platform
July 12, 2019
App Aims To Make Communication Easier for People with Multiple Sclerosis and Their Care Partners
May 31, 2019
Four Things To Watch for at ASCO 2019
May 31, 2019
What’s in Store for CAR T Cell Therapy in Relapsed/Refractory Lymphoma?
May 24, 2019